Study of mirvetuximab soravtansine for FRα-positive ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Your cancer must have progressed (grown or spread) after your most recent treatment.
- You must have a test result (FRα test) showing that your tumor has a certain level of a specific marker (at least 25% of cells with a strong signal).
- You must be well enough to be active (able to do daily activities) and have normal organ function.
- You must have at least one tumor that can be measured on a scan.
- Any side effects from previous treatments (except hair loss) must have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
This study tests an experimental drug called TJ102 for people with advanced ovarian cancer or other solid tumors that have grown despite prior treatments. It aims to see if the drug is safe and effective.
This trial studies a new drug, misetionamide, given alone or with gemcitabine, for people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.